Human immunoglobulin (pH4, Chengdu Rongsheng Pharmaceuticals)

人免疫球蛋白（pH4，成都蓉生）

Report date: 2024/09/11 14:34:07

Base Information

Drug NameHuman immunoglobulin (pH4, Chengdu Rongsheng Pharmaceuticals)
Drug Alias Name蓉生静丙
ClassificationBiologics > Blood componentsBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsAutoimmune DiseasesAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[8] 
Global Approved IndicationsAutoimmune DiseasesAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[7] 
Approved Indications in ChinaAutoimmune DiseasesAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[7] 
Original Approved Country/TerritoryMainland China
Original Approved Date1995/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChengdu Rongsheng Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Rongsheng Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[7] 
Inactive IndicationsInfections

Other Information

ATC CodeJ06BA02
Related LinksWikipediaDrugBankKEGG